Skip to main content

Model Can Predict, Stratify Liver Cancer Risk in Noncirrhotic Chronic Hep B

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 18, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, Sept. 17, 2024 -- A new prognostic model can predict and stratify hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with chronic hepatitis B (CHB), according to a study published online Sept. 17 in the Annals of Internal Medicine.

Gi-Ae Kim, M.D., Ph.D., from Kyung Hee University Hospital in Seoul, South Korea, and colleagues developed and externally validated a prognostic model for HCC risk in noncirrhotic adult patients with CHB, without notable alanine aminotransferase (ALT) elevation. The model was developed in 6,949 patients with CHB from a Korean hospital-based cohort, and was validated externally among 7,429 patients with CHB combined from the Taiwanese cohort and seven cohorts from Korea and Hong Kong.

The researchers found that the derivation and validation cohorts identified 435 and 467 incident HCC cases over 10 and 12 years, respectively. One of the strongest predictors of HCC development was baseline hepatitis B virus DNA level, which demonstrated a nonlinear parabolic association in both cohorts, with the highest risk seen for moderate viral loads. Age, sex, platelet count, ALT levels, and positive hepatitis B e antigen result were additional predictors included in the new model. Satisfactory discrimination and calibration were exhibited by the model, with c-statistics of 0.844 and 0.813 in the derivation and validation cohorts, respectively, with multiple imputation. Greater positive net benefit was yielded in the model compared with other strategies in the 0 to 18 percent threshold.

"This model has the potential to inform optimal medical management strategies for patients with CHB who do not meet the current criteria for antiviral treatment," the authors write.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2024

Read this next

PIVKA-II-Based Model IDs Liver Cancer Risk in Hep C-Related Cirrhosis

THURSDAY, Dec. 5, 2024 -- Among patients with hepatitis C virus (HCV)-related cirrhosis with sustained virological response (SVR) to direct-acting antivirals (DAAs), a serum...

High Rates of Hep C Seen for Patients Presenting to ED With Opioid Overdose

WEDNESDAY, Nov. 13, 2024 -- Patients presenting to emergency departments with opioid overdose have high rates of hepatitis C virus (HCV) infection, according to a study recently...

Palliative Low-Dose Radiotherapy Improves Pain in Hepatic Cancer

TUESDAY, Sept. 10, 2024 -- For adults with hepatocellular carcinoma or liver metastases, low-dose liver radiotherapy plus best supportive care improve pain compared with best...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.